Search results for "Necrosis"

showing 10 items of 1354 documents

Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.

2013

Tumor necrosis factor alpha (TNF-alpha) antagonists have emerged as an effective therapy for patients with diseases as Crohn's disease, rheumatoid arthritis, and other chronic systemic inflammatory diseases. In the last years, there has been a growing interest in the role that inflammatory cytokines, which sustain the pathogenesis of these diseases, plays in regulating cardiac structure and function, particularly in the progression of chronic heart failure. In fact there is an increase of anti-TNF alpha levels in advanced heart failure but the treatment with anti-TNF alpha has been shown to worsen the prognosis of heart failure in randomized controlled trials. Patients with rheumatoid arthr…

medicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAlpha (ethology)DiseaseGastroenterologyProinflammatory cytokinePathogenesisRisk FactorsInternal medicineInternal MedicinemedicineHumansHeart FailureInflammationCrohn's diseaseTumor Necrosis Factor-alphabusiness.industrymedicine.diseaseHeart failureRheumatoid arthritishearth failure.biologicsChronic DiseaseTumor necrosis factor alphabusiness
researchProduct

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

1995

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent. Int J Urol 1995;2:100-1…

medicine.medical_specialtyPathologyUrologyUrologyPhases of clinical researchlaw.inventionlawRecurrencemedicineHumansPapillary transitional cell carcinomaCarcinoma Transitional Cellbusiness.industryTumor Necrosis Factor-alphaRecombinant ProteinRecombinant ProteinsRecombinant Tumor Necrosis Factor-AlphaIntravesical treatmentAdministration IntravesicalTolerabilityUrinary Bladder NeoplasmsToxicityRecombinant DNATumor necrosis factor alphabusinessHuman
researchProduct

2015

Recent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exposed ONJ…

medicine.medical_specialtyPediatricsBisphosphonate-associated osteonecrosis of the jawCross-sectional studybusiness.industryOsteoporosisLarge populationmedicine.diseaseSurgeryExact testOtorhinolaryngologySecondary analysisAntiresorptive AgentsmedicineSurgeryOral SurgeryOsteonecrosis of the jawbusinessBritish Journal of Oral and Maxillofacial Surgery
researchProduct

Kümmell's Disease: Clarifying the Mechanisms and Patients' Inclusion Criteria.

2014

The three major causes of vertebral body collapse include infection, malignant neoplasia, and trauma and it may be difficult to distinguish between them, particularly in the presence of severe osteoporosis. In 1891, however, Dr Hermann Kümmell, further added another possibility of vertebral body crush; the delayed posttraumatic collapse. As originally described, this rare clinical entity includes patients, who after a trivial trauma and an asymptomatic clinical course they develop a progressive vertebral body collapse and a painful kyphosis. Although more than a century has passed from its initial description, only few cases have been reported in the literature, whereas the main pathologic …

medicine.medical_specialtyPediatricsbusiness.industryKyphosisTime lagvertebral body collapseDiseasemedicine.diseaseAsymptomaticArticleSurgeryIntravertebral vacuum cleftresearch reviewKummell's diseasePathognomonicmedicineKümmell’s diseaseSevere osteoporosismedicine.symptomvertebral osteonecrosis.businessCollapse (medical)The open orthopaedics journal
researchProduct

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin blocked mdx mice

2013

The importance of adequate levels of muscle size and function and physical activity is widely recognized. Myostatin/activin blocking increases skeletal muscle mass but may decrease muscle oxidative capacity and can thus be hypothesized to affect voluntary physical activity. Soluble activin receptor IIB (sActRIIB-Fc) was produced to block myostatin/activins. Modestly dystrophic mdx mice were injected with sActRIIB-Fc or PBS with or without voluntary wheel running exercise for 7 wk. Healthy mice served as controls. Running for 7 wk attenuated the sActRIIB-Fc-induced increase in body mass by decreasing fat mass. Running also enhanced/restored the markers of muscle oxidative capacity and autoph…

medicine.medical_specialtyPhysiologyActivin Receptors Type IIEndocrinology Diabetes and MetabolismBlotting WesternCitrate (si)-SynthaseMyostatinMotor ActivityHematocritMuscle hypertrophyEatingHemoglobinsMice03 medical and health sciences0302 clinical medicinePhysical Conditioning AnimalPhysiology (medical)Internal medicineAutophagymedicineAnimalsMuscle Skeletalta315Creatine KinaseAdiposity030304 developmental biology0303 health sciencesbiologymedicine.diagnostic_testTumor Necrosis Factor-alphaBody WeightAutophagySkeletal muscleDNAActivin receptorMyostatinActivinsMice Inbred C57BLmedicine.anatomical_structureEndocrinologyHematocritMice Inbred mdxbiology.proteinCreatine kinaseTumor necrosis factor alphaOxidation-Reduction030217 neurology & neurosurgeryAmerican Journal of Physiology-Endocrinology and Metabolism
researchProduct

Anti-Tumour Necrosis Factor-?? Therapy for Rheumatoid and Other Inflammatory Arthropathies

2006

Anti-tumour necrosis factor (TNF)-alpha represents a major advance in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis. It is usually well tolerated, but a potential increase in the incidence of some infections in patients taking anti-TNFalpha agents has been reported. Compared with younger people, elderly patients have more co-morbidities and are likely to be taking more medications. Moreover, the aging process induces an increase in the rate of infections. Nevertheless, in recent studies analysing the databases of etanercept trials, the normalised incidence of adverse events, serious adverse events, medically important infections and deaths was no…

medicine.medical_specialtyPopulationArthritisSubgroup analysisEtanerceptArthritis RheumatoidPsoriatic arthritisInternal medicinemedicineHumansPharmacology (medical)Adverse effecteducationAgedRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyAnkylosing spondylitisTumor Necrosis Factor-alphabusiness.industryArthritismedicine.diseaseAntirheumatic AgentsRheumatoid arthritisImmunologyGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw

2016

To date there is no consensus on the role of diabetes in the development of medication-related osteonecrosis of the jaws (MR-ONJ). Therefore, this study aimed to investigate the prevalence of diabetes and pathological glucose metabolism in patients with MR-ONJ compared to the general population. All maxillofacial surgery inpatients in one year at our department were investigated regarding diagnosis, anamnesis, medication, and blood glucose readings. 1374 records were analyzed. 35 patients with MR-ONJ were identified. Diabetics accounted for 14.3%. No significant difference in the prevalence of known diabetes was found, except for pathological glucose metabolism in patients with MR-ONJ (p &l…

medicine.medical_specialtyPopulationArticle03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicinediabetes; hyperglycemia; bisphosphonates; denosumab; MR-ONJ; BP-ONJRisk factoreducationGeneral DentistryPathologicalbisphosphonatesAnamnesiseducation.field_of_studyBP-ONJdiabetesbusiness.industrySignificant differencedenosumab030206 dentistrymedicine.diseaseSurgerylcsh:RK1-715Denosumab030220 oncology & carcinogenesislcsh:DentistryMR-ONJhyperglycemiaOsteonecrosis of the jawbusinessmedicine.drugDentistry Journal; Volume 4; Issue 2; Pages: 17
researchProduct

Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells

2003

We have investigated the effects of sex steroids, estradiol (E2), and testosterone (T) on the synthesis of tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) in phorbol-myristate-acetate (PMA)-differentiated human monoblastic U937 cells. The ability of both hormones to modulate the viability and programmed cell death of macrophage-like PMA-differentiated U937 cells was also inspected. E2 increased TNF-alpha synthesis, whereas T had no effect on the production of this cytokine. The combination of E2 and its antagonist tamoxifen or ICI-182,789 completely abolished the induction of TNF-alpha, while combination of T and its antagonist Casodex (CSDX) did not significantly affect …

medicine.medical_specialtyProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentCell BiologyBiologyBiochemistryCell biologyInterleukin 10CytokineEndocrinologyEstrogenApoptosisInternal medicinemedicineMacrophageTumor necrosis factor alphaIL-2 receptorMolecular BiologyJournal of Cellular Biochemistry
researchProduct

Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos’ Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Gröt…

2009

medicine.medical_specialtyProstate cancerBisphosphonate-associated osteonecrosis of the jawLetter to the editorbusiness.industryUrologyGeneral surgerymedicineAdvanced diseasebusinessmedicine.diseaseSurgeryEuropean Urology
researchProduct

Treatment of infected pancreatic necrosis: Outcome in a 9-year, single-center, consecutive series (2006-2014)

2015

medicine.medical_specialtySeries (stratigraphy)Hepatologybusiness.industryEndocrinology Diabetes and MetabolismInternal medicineGastroenterologyMedicineInfected pancreatic necrosisbusinessSingle CenterGastroenterologyPancreatology
researchProduct